Kimberly Yonkers to Female
This is a "connection" page, showing publications Kimberly Yonkers has written about Female.
Connection Strength
2.501
-
Yonkers KA, Altemus M, Gilstad-Hayden K, Kornstein SG, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?: A Randomized Controlled Trial. J Clin Psychopharmacol. 2023 Jul-Aug 01; 43(4):320-325.
Score: 0.048
-
Ondersma SJ, Todd L, Jablonski S, Ahuja C, Gilstad-Hayden K, Goyert G, Loree A, Heffner J, Yonkers KA. Online randomised factorial trial of electronic Screening and Brief Intervention for alcohol use in pregnancy: a study protocol. BMJ Open. 2022 08 03; 12(8):e062735.
Score: 0.046
-
Coy KC, Ko JY, Ondersma SJ, Gilstad-Hayden K, Zapata LB, Chang G, Yonkers K. Association of Prepregnancy Substance Use and Substance Use Disorders with Pregnancy Timing and Intention. J Womens Health (Larchmt). 2022 11; 31(11):1630-1638.
Score: 0.044
-
Forray A, Mele A, Byatt N, Londono Tobon A, Gilstad-Hayden K, Hunkle K, Hong S, Lipkind H, Fiellin DA, Callaghan K, Yonkers KA. Support Models for Addiction Related Treatment (SMART) for pregnant women: Study protocol of a cluster randomized trial of two treatment models for opioid use disorder in prenatal clinics. PLoS One. 2022; 17(1):e0261751.
Score: 0.044
-
Simoni MK, Gilstad-Hayden K, Naqvi SH, Pal L, Yonkers KA. Progression of depression and anxiety symptoms in pregnancies conceived by assisted reproductive technology in the United States. J Psychosom Obstet Gynaecol. 2022 06; 43(2):214-223.
Score: 0.043
-
Forray A, Yonkers KA. The Collision of Mental Health, Substance Use Disorder, and Suicide. Obstet Gynecol. 2021 06 01; 137(6):1083-1090.
Score: 0.042
-
Yonkers KA. Treatment of Psychiatric Conditions in Pregnancy Starts With Planning. Am J Psychiatry. 2021 03 01; 178(3):213-214.
Score: 0.041
-
Olmstead TA, Martino S, Ondersma SJ, Gilstad-Hayden K, Forray A, Yonkers KA. The short-term impact on economic outcomes of SBIRT interventions implemented in reproductive health care settings. J Subst Abuse Treat. 2021 01; 120:108179.
Score: 0.040
-
Yonkers KA, Dailey JI, Gilstad-Hayden K, Ondersma SJ, Forray A, Olmstead TA, Martino S. Abstinence outcomes among women in reproductive health centers administered clinician or electronic brief interventions. J Subst Abuse Treat. 2020 06; 113:107995.
Score: 0.038
-
Wisner KL, Yonkers KA. Are Adverse Reproductive Outcomes Associated With the Illness or Its Treatment (or Both)? JAMA Psychiatry. 2019 12 01; 76(12):1317-1318.
Score: 0.038
-
Chang G, Ondersma SJ, Blake-Lamb T, Gilstad-Hayden K, Orav EJ, Yonkers KA. Identification of substance use disorders among pregnant women: A comparison of screeners. Drug Alcohol Depend. 2019 12 01; 205:107651.
Score: 0.038
-
Martino S, Zimbrean P, Forray A, Kaufman JS, Desan PH, Olmstead TA, Gilstad-Hayden K, Gueorguieva R, Yonkers KA. Implementing Motivational Interviewing for Substance Misuse on Medical Inpatient Units: a Randomized Controlled Trial. J Gen Intern Med. 2019 11; 34(11):2520-2529.
Score: 0.037
-
Ondersma SJ, Chang G, Blake-Lamb T, Gilstad-Hayden K, Orav J, Beatty JR, Goyert GL, Yonkers KA. Accuracy of five self-report screening instruments for substance use in pregnancy. Addiction. 2019 09; 114(9):1683-1693.
Score: 0.037
-
Forray A, Martino S, Gilstad-Hayden K, Kershaw T, Ondersma S, Olmstead T, Yonkers KA. Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic. Addict Behav. 2019 09; 96:156-163.
Score: 0.036
-
Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, Blake-Lamb T, Guille C, Landau R, Minkoff H, Prabhu M, Rosenthal E, Terplan M, Wright TE, Yonkers KA. Substance use disorders in pregnancy: clinical,?ethical, and research imperatives of?the?opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction Medicine. Am J Obstet Gynecol. 2019 07; 221(1):B5-B28.
Score: 0.036
-
Thibaut F, Chagraoui A, Buckley L, Gressier F, Labad J, Lamy S, Potenza MN, Rondon M, Riecher-R?ssler A, Soyka M, Yonkers K. WFSBP * and IAWMH ** Guidelines for the treatment of alcohol use disorders in pregnant women. World J Biol Psychiatry. 2019 01; 20(1):17-50.
Score: 0.036
-
Martino S, Ondersma SJ, Forray A, Olmstead TA, Gilstad-Hayden K, Howell HB, Kershaw T, Yonkers KA. A randomized controlled trial of screening and brief interventions for substance misuse in reproductive health. Am J Obstet Gynecol. 2018 03; 218(3):322.e1-322.e12.
Score: 0.033
-
Yonkers KA, Gilstad-Hayden K, Forray A, Lipkind HS. Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes. JAMA Psychiatry. 2017 11 01; 74(11):1145-1152.
Score: 0.033
-
Loree AM, Gariepy A, Ruger JP, Yonkers KA. Postpartum Contraceptive use and Rapid Repeat Pregnancy Among Women who use Substances. Subst Use Misuse. 2018 01 02; 53(1):162-169.
Score: 0.033
-
Forray A, Gilstad-Hayden K, Suppies C, Bogen D, Sofuoglu M, Yonkers KA. Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. Psychoneuroendocrinology. 2017 Dec; 86:96-103.
Score: 0.032
-
Yonkers KA, Forray A, Smith MV. Maternal Antidepressant Use and Pregnancy Outcomes. JAMA. 2017 08 15; 318(7):665-666.
Score: 0.032
-
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 01; 218(1):68-74.
Score: 0.032
-
Yonkers KA, Cameron B, Gueorguieva R, Altemus M, Kornstein SG. The Influence of Cyclic Hormonal Contraception on Expression of Premenstrual Syndrome. J Womens Health (Larchmt). 2017 Apr; 26(4):321-328.
Score: 0.031
-
Gariepy AM, Lundsberg LS, Miller D, Stanwood NL, Yonkers KA. Are pregnancy planning and pregnancy timing associated with maternal psychiatric illness, psychological distress and support during pregnancy? J Affect Disord. 2016 Nov 15; 205:87-94.
Score: 0.030
-
Smith MV, Gotman N, Yonkers KA. Early Childhood Adversity and Pregnancy Outcomes. Matern Child Health J. 2016 Apr; 20(4):790-8.
Score: 0.029
-
Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Oct; 72(10):1037-44.
Score: 0.028
-
Gariepy AM, Lundsberg LS, Stolar M, Stanwood NL, Yonkers KA. Are pregnancy planning and timing associated with preterm or small for gestational age births? Fertil Steril. 2015 Dec; 104(6):1484-92.
Score: 0.028
-
Forray A, Merry B, Lin H, Ruger JP, Yonkers KA. Perinatal substance use: a prospective evaluation of abstinence and relapse. Drug Alcohol Depend. 2015 May 01; 150:147-55.
Score: 0.027
-
Smith MV, Costello D, Yonkers KA. Clinical correlates of prescription opioid analgesic use in pregnancy. Matern Child Health J. 2015 Mar; 19(3):548-56.
Score: 0.027
-
Yonkers KA, Smith MV, Forray A, Epperson CN, Costello D, Lin H, Belanger K. Pregnant women with posttraumatic stress disorder and risk of preterm birth. JAMA Psychiatry. 2014 Aug; 71(8):897-904.
Score: 0.026
-
Hartlage SA, Breaux CA, Yonkers KA. Addressing concerns about the inclusion of premenstrual dysphoric disorder in DSM-5. J Clin Psychiatry. 2014 Jan; 75(1):70-6.
Score: 0.025
-
Forray A, Gotman N, Kershaw T, Yonkers KA. Perinatal smoking and depression in women with concurrent substance use. Addict Behav. 2014 Apr; 39(4):749-56.
Score: 0.025
-
Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014; 10:369-92.
Score: 0.025
-
Yonkers KA, Pearlstein TB, Gotman N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol. 2013 Oct; 33(5):614-20.
Score: 0.025
-
Yonkers KA. The possible effects of depressive symptoms on risk of preterm birth are clouded by lack of control over confounding factors. Evid Based Med. 2013 Oct; 18(5):194-5.
Score: 0.024
-
Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA. Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum Dev. 2013 Feb; 89(2):81-6.
Score: 0.023
-
Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, Luchansky E, Lin H, Belanger K. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology. 2012 Sep; 23(5):677-85.
Score: 0.023
-
Yonkers KA, Forray A, Howell HB, Gotman N, Kershaw T, Rounsaville BJ, Carroll KM. Motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice: a randomized trial for treatment of hazardous substance use in pregnancy and after delivery. Gen Hosp Psychiatry. 2012 Sep-Oct; 34(5):439-49.
Score: 0.023
-
Quesada O, Gotman N, Howell HB, Funai EF, Rounsaville BJ, Yonkers KA. Prenatal hazardous substance use and adverse birth outcomes. J Matern Fetal Neonatal Med. 2012 Aug; 25(8):1222-7.
Score: 0.022
-
Epperson CN, Steiner M, Hartlage SA, Eriksson E, Schmidt PJ, Jones I, Yonkers KA. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry. 2012 May; 169(5):465-75.
Score: 0.022
-
Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry. 2012 Mar; 69(3):300-5.
Score: 0.022
-
Davis KJ, Yonkers KA. Making lemonade out of lemons: a case report and literature review of external pressure as an intervention with pregnant and parenting substance-using women. J Clin Psychiatry. 2012 Jan; 73(1):51-6.
Score: 0.022
-
Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K, Brunetto WL, Lin H, Burkman RT, Zelop CM, Lockwood CJ. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology. 2011 Nov; 22(6):848-54.
Score: 0.022
-
Smith MV, Shao L, Howell H, Lin H, Yonkers KA. Perinatal depression and birth outcomes in a Healthy Start project. Matern Child Health J. 2011 Apr; 15(3):401-9.
Score: 0.021
-
Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstet Gynecol. 2011 Apr; 117(4):961-977.
Score: 0.021
-
Buist A, Gotman N, Yonkers KA. Generalized anxiety disorder: course and risk factors in pregnancy. J Affect Disord. 2011 Jun; 131(1-3):277-83.
Score: 0.020
-
Leibenluft E, Yonkers KA. The ties that bind: maternal-infant interactions and the neural circuitry of postpartum depression. Am J Psychiatry. 2010 Nov; 167(11):1294-6.
Score: 0.020
-
Yonkers KA, Gotman N, Kershaw T, Forray A, Howell HB, Rounsaville BJ. Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale. Obstet Gynecol. 2010 Oct; 116(4):827-833.
Score: 0.020
-
Smith MV, Gotman N, Lin H, Yonkers KA. Do the PHQ-8 and the PHQ-2 accurately screen for depressive disorders in a sample of pregnant women? Gen Hosp Psychiatry. 2010 Sep-Oct; 32(5):544-8.
Score: 0.020
-
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009 Sep-Oct; 31(5):403-13.
Score: 0.019
-
Yonkers KA, Smith MV, Gotman N, Belanger K. Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive disorder. Gen Hosp Psychiatry. 2009 Jul-Aug; 31(4):327-33.
Score: 0.018
-
Yonkers KA, Howell HB, Allen AE, Ball SA, Pantalon MV, Rounsaville BJ. A treatment for substance abusing pregnant women. Arch Womens Ment Health. 2009 Aug; 12(4):221-7.
Score: 0.018
-
Yonkers KA, Smith MV, Lin H, Howell HB, Shao L, Rosenheck RA. Depression screening of perinatal women: an evaluation of the healthy start depression initiative. Psychiatr Serv. 2009 Mar; 60(3):322-8.
Score: 0.018
-
Yonkers KA. Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy. Am J Psychiatry. 2009 Mar; 166(3):268-70.
Score: 0.018
-
Smith MV, Shao L, Howell H, Wang H, Poschman K, Yonkers KA. Success of mental health referral among pregnant and postpartum women with psychiatric distress. Gen Hosp Psychiatry. 2009 Mar-Apr; 31(2):155-62.
Score: 0.018
-
Spoozak L, Gotman N, Smith MV, Belanger K, Yonkers KA. Evaluation of a social support measure that may indicate risk of depression during pregnancy. J Affect Disord. 2009 Apr; 114(1-3):216-23.
Score: 0.017
-
Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 05; 371(9619):1200-10.
Score: 0.017
-
Wallenstein GV, Blaisdell-Gross B, Gajria K, Guo A, Hagan M, Kornstein SG, Yonkers KA. Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool. J Womens Health (Larchmt). 2008 Apr; 17(3):439-50.
Score: 0.017
-
Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry. 2008 Apr; 69(4):659-65.
Score: 0.017
-
Yonkers KA. The treatment of women suffering from depression who are either pregnant or breastfeeding. Am J Psychiatry. 2007 Oct; 164(10):1457-9.
Score: 0.016
-
Borenstein JE, Dean BB, Leifke E, Korner P, Yonkers KA. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt). 2007 Oct; 16(8):1139-44.
Score: 0.016
-
Halbreich U, Backstrom T, Eriksson E, O'brien S, Calil H, Ceskova E, Dennerstein L, Douki S, Freeman E, Genazzani A, Heuser I, Kadri N, Rapkin A, Steiner M, Wittchen HU, Yonkers K. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol. 2007 Mar; 23(3):123-30.
Score: 0.016
-
Rogal SS, Poschman K, Belanger K, Howell HB, Smith MV, Medina J, Yonkers KA. Effects of posttraumatic stress disorder on pregnancy outcomes. J Affect Disord. 2007 Sep; 102(1-3):137-43.
Score: 0.016
-
Dean BB, Borenstein JE, Knight K, Yonkers K. Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt). 2006 Jun; 15(5):546-55.
Score: 0.015
-
Smith MV, Poschman K, Cavaleri MA, Howell HB, Yonkers KA. Symptoms of posttraumatic stress disorder in a community sample of low-income pregnant women. Am J Psychiatry. 2006 May; 163(5):881-4.
Score: 0.015
-
Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):198-202.
Score: 0.015
-
Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C, Roberts DL, Yonkers K. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health (Larchmt). 2006 Jan-Feb; 15(1):57-69.
Score: 0.014
-
Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec; 72(6):414-21.
Score: 0.014
-
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3):492-501.
Score: 0.014
-
Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
Score: 0.014
-
Lynn T, Kelleher ME, Georges HM, McCauley EM, Logan RW, Yonkers KA, Abrahams VM. Buprenorphine induces human fetal membrane sterile inflammation. J Reprod Immunol. 2025 Mar; 168:104445.
Score: 0.014
-
Yonkers KA. Management strategies for PMS/PMDD. J Fam Pract. 2004 Sep; Suppl:S15-20.
Score: 0.013
-
Brawman-Mintzer O, Yonkers KA. New trends in the treatment of anxiety disorders. CNS Spectr. 2004 Aug; 9(8 Suppl 7):19-27.
Score: 0.013
-
Kaufman JS, Yonkers KA, Maltz C, Friedhoff CM, Londo?o Tobon A, Mele A, Tessier-Kay M, Grechukhina O, Lipkind H, Byatt N, Forray A. Reporting Perinatal Substance Use to Child Protective Services: Obstetric Provider Perspectives on the Impact on Care. J Womens Health (Larchmt). 2024 Nov; 33(11):1501-1508.
Score: 0.013
-
Doernberg M, Gilstad-Hayden K, Yonkers KA, Forray A. Provider-patient relationships and trauma among pregnant patients with opioid-use disorder. Am J Addict. 2024 Sep; 33(5):569-575.
Score: 0.013
-
Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L, Miller L, Manber R, Viguera A, Suppes T, Altshuler L. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry. 2004 Apr; 161(4):608-20.
Score: 0.013
-
Smith MV, Rosenheck RA, Cavaleri MA, Howell HB, Poschman K, Yonkers KA. Screening for and detection of depression, panic disorder, and PTSD in public-sector obstetric clinics. Psychiatr Serv. 2004 Apr; 55(4):407-14.
Score: 0.013
-
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Arch Womens Ment Health. 2003 Nov; 6(4):287-92.
Score: 0.012
-
Borenstein JE, Dean BB, Endicott J, Wong J, Brown C, Dickerson V, Yonkers KA. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003 Jul; 48(7):515-24.
Score: 0.012
-
Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003; 17(3):173-9.
Score: 0.012
-
Yonkers KA. Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes. Psychopharmacol Bull. 2003; 37 Suppl 1:135-47.
Score: 0.012
-
Yonkers KA. Special issues related to the treatment of depression in women. J Clin Psychiatry. 2003; 64 Suppl 18:8-13.
Score: 0.012
-
Fabrizio VA, Lindsay CV, Wilcox M, Hong S, Lynn T, Norwitz ER, Yonkers KA, Abrahams VM. The serotonin reuptake inhibitor fluoxetine induces human fetal membrane sterile inflammation through p38 MAPK activation. J Reprod Immunol. 2023 02; 155:103786.
Score: 0.012
-
Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin Pharmacother. 2002 Jul; 3(7):979-91.
Score: 0.011
-
Yonkers KA, Brawman-Mintzer O. The pharmacologic treatment of depression: is gender a critical factor? J Clin Psychiatry. 2002 Jul; 63(7):610-5.
Score: 0.011
-
Handy AB, Greenfield SF, Yonkers KA, Payne LA. Psychiatric Symptoms Across the Menstrual Cycle in Adult Women: A Comprehensive Review. Harv Rev Psychiatry. 2022 Mar-Apr 01; 30(2):100-117.
Score: 0.011
-
Yonkers KA, Ramin SM, Rush AJ, Navarrete CA, Carmody T, March D, Heartwell SF, Leveno KJ. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry. 2001 Nov; 158(11):1856-63.
Score: 0.011
-
Adams ZM, Ginapp CM, Price CR, Qin Y, Madden LM, Yonkers K, Meyer JP. "A good mother": Impact of motherhood identity on women's substance use and engagement in treatment across the lifespan. J Subst Abuse Treat. 2021 11; 130:108474.
Score: 0.010
-
Yonkers KA, Dyck IR, Keller MB. An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women. Psychiatr Serv. 2001 May; 52(5):637-43.
Score: 0.010
-
Howell HB, Brawman-Mintzer O, Monnier J, Yonkers KA. Generalized anxiety disorder in women. Psychiatr Clin North Am. 2001 Mar; 24(1):165-78.
Score: 0.010
-
Krystal JH, Alvarado J, Ball SA, Fortunati FG, Hu M, Ivy ME, Kapo J, Olson KD, Rohrbaugh RM, Sinha R, Tebes JK, Vender RJ, Yonkers KA, Mayes LC. Mobilizing an institutional supportive response for healthcare workers and other staff in the context of COVID-19: The Yale experience. Gen Hosp Psychiatry. 2021 Jan-Feb; 68:12-18.
Score: 0.010
-
Serowik KL, Yonkers KA, Gilstad-Hayden K, Forray A, Zimbrean P, Martino S. Substance Use Disorder Detection Rates Among Providers of General Medical Inpatients. J Gen Intern Med. 2021 03; 36(3):668-675.
Score: 0.010
-
Lundsberg LS, Cutler AS, Stanwood NL, Yonkers KA, Gariepy AM. Association of Pregnancy Contexts with Depression and Low Social Support in Early Pregnancy. Perspect Sex Reprod Health. 2020 09; 52(3):161-170.
Score: 0.010
-
Olmstead TA, Yonkers KA, Forray A, Zimbrean P, Gilstad-Hayden K, Martino S. Cost and cost-effectiveness of three strategies for implementing motivational interviewing for substance misuse on medical inpatient units. Drug Alcohol Depend. 2020 09 01; 214:108156.
Score: 0.010
-
Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000 Jun; 176:544-9.
Score: 0.010
-
Kamody RC, Yonkers K, Pluhar EI, Olezeski CL. Disordered Eating Among Trans-Masculine Youth: Considerations Through a Developmental Lens. LGBT Health. 2020 May/Jun; 7(4):170-173.
Score: 0.010
-
Jones RD, Miller J, Vitous CA, Krenz C, Brady KT, Brown AJ, Daumit GL, Drake AF, Fraser VJ, Hartmann KE, Hochman JS, Girdler S, Kalet AL, Libby AM, Mangurian C, Regensteiner JG, Yonkers K, Jagsi R. From Stigma to Validation: A Qualitative Assessment of a Novel National Program to Improve Retention of Physician-Scientists with Caregiving Responsibilities. J Womens Health (Larchmt). 2020 12; 29(12):1547-1558.
Score: 0.010
-
Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 2000 Feb; 61(2):101-9.
Score: 0.010
-
Jones RD, Miller J, Vitous CA, Krenz C, Brady KT, Brown AJ, Daumit GL, Drake AF, Fraser VJ, Hartmann KE, Hochman JS, Girdler S, Libby AM, Mangurian C, Regensteiner JG, Yonkers K, Jagsi R. The Most Valuable Resource Is Time: Insights From a Novel National Program to Improve Retention of Physician-Scientists With Caregiving Responsibilities. Acad Med. 2019 11; 94(11):1746-1756.
Score: 0.009
-
Levis B, McMillan D, Sun Y, He C, Rice DB, Krishnan A, Wu Y, Azar M, Sanchez TA, Chiovitti MJ, Bhandari PM, Neupane D, Saadat N, Riehm KE, Imran M, Boruff JT, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Vigod SN, Aceti F, Alvarado R, Alvarado-Esquivel C, Bakare MO, Barnes J, Beck CT, Bindt C, Boyce PM, Bunevicius A, Couto TCE, Chaudron LH, Correa H, de Figueiredo FP, Eapen V, Fernandes M, Figueiredo B, Fisher JRW, Garcia-Esteve L, Giardinelli L, Helle N, Howard LM, Khalifa DS, Kohlhoff J, Kusminskas L, Kozinszky Z, Lelli L, Leonardou AA, Lewis BA, Maes M, Meuti V, Nakic Rado? S, Navarro Garc?a P, Nishi D, Okitundu Luwa E-Andjafono D, Robertson-Blackmore E, Rochat TJ, Rowe HJ, Siu BWM, Skalkidou A, Stein A, Stewart RC, Su KP, Sundstr?m-Poromaa I, Tadinac M, Tandon SD, Tendais I, Thiagayson P, T?reki A, Torres-Gim?nez A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Wynter K, Yonkers KA, Benedetti A, Thombs BD. Comparison of major depression diagnostic classification probability using the SCID, CIDI, and MINI diagnostic interviews among women in pregnancy or postpartum: An individual participant data meta-analysis. Int J Methods Psychiatr Res. 2019 12; 28(4):e1803.
Score: 0.009
-
Leibenluft E, Ashman SB, Feldman-Naim S, Yonkers KA. Lack of relationship between menstrual cycle phase and mood in a sample of women with rapid cycling bipolar disorder. Biol Psychiatry. 1999 Aug 15; 46(4):577-80.
Score: 0.009
-
Olmstead TA, Yonkers KA, Ondersma SJ, Forray A, Gilstad-Hayden K, Martino S. Cost-effectiveness of electronic- and clinician-delivered screening, brief intervention and referral to treatment for women in reproductive health centers. Addiction. 2019 09; 114(9):1659-1669.
Score: 0.009
-
Yonkers KA. Medical management of premenstrual dysphoric disorder. J Gend Specif Med. 1999 May-Jun; 2(3):55-60.
Score: 0.009
-
Loree AM, Yonkers KA, Ondersma SJ, Gilstad-Hayden K, Martino S. Comparing satisfaction, alliance and intervention components in electronically delivered and in-person brief interventions for substance use among childbearing-aged women. J Subst Abuse Treat. 2019 04; 99:1-7.
Score: 0.009
-
Lundsberg LS, Peglow S, Qasba N, Yonkers KA, Gariepy AM. Is Preconception Substance Use Associated With Unplanned or Poorly Timed Pregnancy? J Addict Med. 2018 Jul/Aug; 12(4):321-328.
Score: 0.009
-
Yonkers KA, Zlotnick C, Allsworth J, Warshaw M, Shea T, Keller MB. Is the course of panic disorder the same in women and men? Am J Psychiatry. 1998 May; 155(5):596-602.
Score: 0.008
-
Jagsi R, Jones RD, Griffith KA, Brady KT, Brown AJ, Davis RD, Drake AF, Ford D, Fraser VJ, Hartmann KE, Hochman JS, Girdler S, Libby AM, Mangurian C, Regensteiner JG, Yonkers K, Escobar-Alvarez S, Myers ER. An Innovative Program to Support Gender Equity and Success in Academic Medicine: Early Experiences From the Doris Duke Charitable Foundation's Fund to Retain Clinical Scientists. Ann Intern Med. 2018 07 17; 169(2):128-130.
Score: 0.008
-
Yonkers KA. Assessing unipolar mood disorders in women. Psychopharmacol Bull. 1998; 34(3):261-6.
Score: 0.008
-
Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24; 278(12):983-8.
Score: 0.008
-
Ko JY, Wolicki S, Barfield WD, Patrick SW, Broussard CS, Yonkers KA, Naimon R, Iskander J. CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2017 Mar 10; 66(9):242-245.
Score: 0.008
-
Xu X, Yonkers KA, Ruger JP. Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial. BMC Pregnancy Childbirth. 2017 03 07; 17(1):83.
Score: 0.008
-
Gariepy A, Lundsberg LS, Vilardo N, Stanwood N, Yonkers K, Schwarz EB. Pregnancy context and women's health-related quality of life. Contraception. 2017 May; 95(5):491-499.
Score: 0.008
-
Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders? J Clin Psychiatry. 1997; 58 Suppl 3:62-7; discussion 68-9.
Score: 0.008
-
Yonkers KA, Clark RH, Trivedi MH. The psychopharmacological treatment of nonmajor mood disorders. Mod Probl Pharmacopsychiatry. 1997; 25:146-66.
Score: 0.008
-
Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997; 58 Suppl 14:4-10; discussion 11-3.
Score: 0.008
-
Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry. 1997; 58 Suppl 15:19-25.
Score: 0.008
-
Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, Creanga AA. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016 Nov; 215(5):539-547.
Score: 0.007
-
Yonkers KA, Ellison JM, Shera DM, Pratt LA, Cole JO, Fierman E, Keller MB, Lavori PW. Description of antipanic therapy in a prospective longitudinal study. J Clin Psychopharmacol. 1996 Jun; 16(3):223-32.
Score: 0.007
-
Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996 Mar; 168(3):308-13.
Score: 0.007
-
Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb; 16(1):3-8.
Score: 0.007
-
Yonkers KA, Halbreich U, Freeman E, Brown C, Pearlstein T. Sertraline in the treatment of premenstrual dysphoric disorder. Psychopharmacol Bull. 1996; 32(1):41-6.
Score: 0.007
-
Yonkers KA, Chantilis SJ. Recognition of depression in obstetric/gynecology practices. Am J Obstet Gynecol. 1995 Aug; 173(2):632-8.
Score: 0.007
-
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. Obstet Gynecol. 2015 May; 125(5):1224-1235.
Score: 0.007
-
Armitage R, Yonkers KA. Case report: menstrual-related very short REM latency in a healthy normal control. Sleep. 1994 Jun; 17(4):345-7.
Score: 0.006
-
Xu X, Yonkers KA, Ruger JP. Costs of a motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice for pregnant substance users. PLoS One. 2014; 9(4):e95264.
Score: 0.006
-
Cole-Lewis HJ, Kershaw TS, Earnshaw VA, Yonkers KA, Lin H, Ickovics JR. Pregnancy-specific stress, preterm birth, and gestational age among high-risk young women. Health Psychol. 2014 Sep; 33(9):1033-45.
Score: 0.006
-
Yonkers KA, Harrison W. The inclusion of women in psychopharmacologic trials. J Clin Psychopharmacol. 1993 Dec; 13(6):380-2.
Score: 0.006
-
Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush AJ, Thase ME, Yonkers KA, Rapaport MH. The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis. J Clin Psychiatry. 2013 Nov; 74(11):1084-91.
Score: 0.006
-
Huang H, Coleman S, Bridge JA, Yonkers K, Katon W. A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight. Gen Hosp Psychiatry. 2014 Jan-Feb; 36(1):13-8.
Score: 0.006
-
Severino SK, Yonkers KA. A literature review of psychotic symptoms associated with the premenstruum. Psychosomatics. 1993 Jul-Aug; 34(4):299-306.
Score: 0.006
-
Garlow SJ, Kinkead B, Thase ME, Judd LL, Rush AJ, Yonkers KA, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH. Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res. 2013 Sep; 47(9):1199-203.
Score: 0.006
-
Nevatte T, O'Brien PM, B?ckstr?m T, Brown C, Dennerstein L, Endicott J, Epperson CN, Eriksson E, Freeman EW, Halbreich U, Ismail K, Panay N, Pearlstein T, Rapkin A, Reid R, Rubinow D, Schmidt P, Steiner M, Studd J, Sundstr?m-Poromaa I, Yonkers K. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013 Aug; 16(4):279-91.
Score: 0.006
-
Reich J, Warshaw M, Peterson LG, White K, Keller M, Lavori P, Yonkers KA. Comorbidity of panic and major depressive disorder. J Psychiatr Res. 1993; 27 Suppl 1:23-33.
Score: 0.006
-
Yonkers KA, White K. Premenstrual exacerbation of depression: one process or two? J Clin Psychiatry. 1992 Aug; 53(8):289-92.
Score: 0.006
-
Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992 May; 149(5):587-95.
Score: 0.006
-
Yonkers KA, Ellison JM, Shera DM, Pratt LA, Langford LM, Cole JO, White K, Lavori PW, Keller MB. Pharmacotherapy observed in a large prospective longitudinal study on anxiety disorders. Psychopharmacol Bull. 1992; 28(2):131-7.
Score: 0.005
-
Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009; 17(2):120-37.
Score: 0.004
-
Bernstein IH, Rush AJ, Yonkers K, Carmody TJ, Woo A, McConnell K, Trivedi MH. Symptom features of postpartum depression: are they distinct? Depress Anxiety. 2008; 25(1):20-6.
Score: 0.004
-
Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol. 2007 May; 109(5):1068-75.
Score: 0.004
-
Halbreich U, O'Brien PM, Eriksson E, B?ckstr?m T, Yonkers KA, Freeman EW. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006; 20(7):523-47.
Score: 0.004
-
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keller MB. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005 Jun; 162(6):1179-87.
Score: 0.003
-
Pearlstein T, Yonkers KA, Fayyad R, Gillespie JA. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005 Apr; 85(3):275-82.
Score: 0.003
-
Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G. Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry. 2004 Oct; 161(10):1864-71.
Score: 0.003
-
Perkonigg A, Yonkers KA, Pfister H, Lieb R, Wittchen HU. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry. 2004 Oct; 65(10):1314-22.
Score: 0.003
-
Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
Score: 0.003
-
Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
Score: 0.003
-
Le Bon O, Yonkers K, Armitage R. More sleep cycles in the mid-luteal phase of a healthy control. Acta Neurol Belg. 2002 Dec; 102(4):186-7.
Score: 0.003
-
Rapaport MH, Judd LL, Schettler PJ, Yonkers KA, Thase ME, Kupfer DJ, Frank E, Plewes JM, Tollefson GD, Rush AJ. A descriptive analysis of minor depression. Am J Psychiatry. 2002 Apr; 159(4):637-43.
Score: 0.003
-
Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001 Nov; 98(5 Pt 1):737-44.
Score: 0.003
-
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison W, Davis SM, Keller MB. Gender differences in chronic major and double depression. J Affect Disord. 2000 Oct; 60(1):1-11.
Score: 0.003
-
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, Gelenberg AJ, Davis SM, Harrison WM, Keller MB. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry. 2000 Sep; 157(9):1445-52.
Score: 0.002
-
Gurguis GN, Yonkers KA, Phan SP, Blakeley JE, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry. 1998 Oct 01; 44(7):600-9.
Score: 0.002
-
Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, Vogel GW, Kaplita SB, Fleming JB, Montplaisir J, Erman MK, Albala BJ, McQuade RD. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998 Jul 01; 44(1):3-14.
Score: 0.002
-
Gurguis GN, Yonkers KA, Blakeley JE, Phan SP, Williams A, Rush AJ. Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Res. 1998 Jun 02; 79(1):31-42.
Score: 0.002
-
Armitage R, Yonkers K, Cole D, Rush AJ. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol. 1997 Jun; 17(3):161-8.
Score: 0.002
-
Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, Rosenbaum J, Halbreich U. Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry. 1997 Mar; 154(3):390-5.
Score: 0.002
-
Shelton RC, Davidson J, Yonkers KA, Koran L, Thase ME, Pearlstein T, Halbreich U. The undertreatment of dysthymia. J Clin Psychiatry. 1997 Feb; 58(2):59-65.
Score: 0.002
-
Goldenberg IM, White K, Yonkers K, Reich J, Warshaw MG, Goisman RM, Keller MB. The infrequency of "pure culture" diagnoses among the anxiety disorders. J Clin Psychiatry. 1996 Nov; 57(11):528-33.
Score: 0.002
-
Halbreich U, Petty F, Yonkers K, Kramer GL, Rush AJ, Bibi KW. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry. 1996 May; 153(5):718-20.
Score: 0.002
-
Kornstein SG, Schatzberg AF, Yonkers KA, Thase ME, Keitner GI, Ryan CE, Schlager D. Gender differences in presentation of chronic major depression. Psychopharmacol Bull. 1995; 31(4):711-8.
Score: 0.002
-
Keller MB, Yonkers KA, Warshaw MG, Pratt LA, Gollan JK, Massion AO, White K, Swartz AR, Reich J, Lavori PW. Remission and relapse in subjects with panic disorder and panic with agoraphobia: a prospective short-interval naturalistic follow-up. J Nerv Ment Dis. 1994 May; 182(5):290-6.
Score: 0.002
-
Rogers MP, White K, Warshaw MG, Yonkers KA, Rodriguez-Villa F, Chang G, Keller MB. Prevalence of medical illness in patients with anxiety disorders. Int J Psychiatry Med. 1994; 24(1):83-96.
Score: 0.002
-
Fierman EJ, Hunt MF, Pratt LA, Warshaw MG, Yonkers KA, Peterson LG, Epstein-Kaye TM, Norton HS. Trauma and posttraumatic stress disorder in subjects with anxiety disorders. Am J Psychiatry. 1993 Dec; 150(12):1872-4.
Score: 0.002
-
Warshaw MG, Fierman E, Pratt L, Hunt M, Yonkers KA, Massion AO, Keller MB. Quality of life and dissociation in anxiety disorder patients with histories of trauma or PTSD. Am J Psychiatry. 1993 Oct; 150(10):1512-6.
Score: 0.002